Published in AIDS Behav on June 28, 2016
Integrated HIV care and service engagement among people living with HIV who use drugs in a setting with a community-wide treatment as prevention initiative: a qualitative study in Vancouver, Canada. J Int AIDS Soc (2017) 0.76
Development of a Conceptual Etiological Model of Treatment Regimen Fatigue Among Patients Engaged in HIV Care: A Qualitative Study. J Assoc Nurses AIDS Care (2017) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Qualitative data analysis for health services research: developing taxonomy, themes, and theory. Health Serv Res (2007) 10.21
Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA (2000) 10.17
Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS (1997) 9.08
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science (2013) 8.24
Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis (2006) 7.42
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med (2003) 4.27
Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr (2001) 3.83
Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77
Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55
Structural vulnerability and health: Latino migrant laborers in the United States. Med Anthropol (2011) 2.36
Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One (2014) 2.20
AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV (2015) 2.09
Development of antiretroviral drug resistance. N Engl J Med (2011) 1.88
Attaining higher goals in HIV treatment: the central importance of adherence. AIDS (1999) 1.88
Determinants of HAART discontinuation among injection drug users. AIDS Care (2005) 1.74
Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med (2006) 1.74
Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr (2010) 1.68
Treatment as prevention--a double hat-trick. Lancet (2011) 1.63
Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy (2009) 1.63
Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr (2009) 1.54
Vienna Declaration: a call for evidence-based drug policies. Lancet (2010) 1.52
Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA (2012) 1.48
Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS (2012) 1.40
The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care (2009) 1.38
Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDS (2011) 1.33
HIV treatment as prevention among injection drug users. Curr Opin HIV AIDS (2012) 1.23
Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One (2012) 1.22
Barriers to HIV treatment among people who use injection drugs: implications for 'treatment as prevention'. Curr Opin HIV AIDS (2012) 1.22
Housing status and the health of people living with HIV/AIDS. Curr HIV/AIDS Rep (2012) 1.13
Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and research needs. J Acquir Immune Defic Syndr (2010) 1.12
Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther (2010) 1.10
Treatment as prevention: preparing the way. J Int AIDS Soc (2011) 1.09
A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med (2014) 1.01
Interdisciplinary mixed methods research with structurally vulnerable populations: case studies of injection drug users in San Francisco. Int J Drug Policy (2013) 0.98
Extending drug ethno-epidemiology using agent-based modelling. Addiction (2009) 0.98
Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study. Soc Sci Med (2015) 0.95
Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States. J Acquir Immune Defic Syndr (2014) 0.95
Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep (2014) 0.87
HAART slows progression to anal cancer in HIV-infected MSM. AIDS (2015) 0.85
Injection drug use and HIV antiretroviral therapy discontinuation in a Canadian setting. AIDS Behav (2013) 0.84
Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada. HIV Med (2014) 0.83
Correlates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia. AIDS Behav (2014) 0.83
Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden. AIDS Care (2013) 0.82
Characterizing retention in HAART as a recurrent event process: insights into 'cascade churn'. AIDS (2015) 0.81
Impact of supervised drug consumption services on access to and engagement with care at a palliative and supportive care facility for people living with HIV/AIDS: a qualitative study. J Int AIDS Soc (2014) 0.80
Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. AIDS Care (2015) 0.78